Furthermore, there was no significant inflammation observed; mice saw increased lifespans, with 40% survival after 40 days following aPD1-GOx-MN treatment and about 70% of T-cell promoting anti-CTLA4 antibody and aPDI treated mice being cancer-free beyond 60 days when the MN patch was used. Here, CTLA4 is linked to cancer.